ClinicalTrials.gg
RecruitingNCT06813586DataNetCPUpdated Feb 7, 2025

Observational Study for the Epidemiology of Cerebral Palsy in Italy

An observational study in Cerebral Palsy, sponsored by IRCCS Fondazione Stella Maris. Recruiting at 3 sites in Italy. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by IRCCS Fondazione Stella Maris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
300
Ages
4 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Cerebral Palsy by IRCCS Fondazione Stella Maris — 10 open to participants now, 10 under way, none of them phase 3. Cerebral Palsy · IRCCS Fondazione Stella Maris.

Started
2023
with 2 others
Observational
8 of 16
6 open now
Registered
13th of 16
by date

Among the 16 studies in Cerebral Palsy by IRCCS Fondazione Stella Maris, this one is one of 3 that started in 2023, is one of 8 observational ones, and was the 13th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

10 of the 16 studies in Cerebral Palsy by IRCCS Fondazione Stella Maris are open now, in 2 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 4 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Cerebral Palsy by IRCCS Fondazione Stella Maris, or all of them as a file.
02

Study summary

BACKGROUND AND RATIONALE Cerebral Palsy (CP) is the leading cause of childhood disability, with an estimated prevalence of 2 to 2.5 per 1,000 births. This complex clinical condition encompasses motor development disorders as well as sensory, communication, cognitive, and emotional impairments. Despite the significant healthcare impact of CP, standardized guidelines for its study and treatment are lacking both nationally and internationally. Existing literature is limited by small sample sizes, inconsistent assessment tools, and insufficient etiopathogenetic and functional characterizations of different CP types. A national registry, which could offer comprehensive epidemiological data, does not currently exist.

This project aims to create a shared digital platform across clinical centers throughout Italy (three coordinative centers for northern, central, and southern Italy). This platform will allow systematic, standardized, retrospective, and prospective data collection, including clinical, instrumental, and genetic data (where available) for patients with CP. The study intends to complement ongoing national projects, such as the "Italian Network for Early Detection and Intervention in Developmental Disabilities (INEED)" and the "Italian Network for Cerebral Palsy (Ita-Net-CP)."

STUDY OBJECTIVES

This study aims to analyze epidemiological data, specifically:

  • Evaluating the prevalence of various clinical types of CP
  • Assessing the distribution of functional impairment severity and associated comorbidities.

STUDY DESIGN This is a non-profit, multicenter, observational study involving a cohort of CP patients, promoted within the Mariani Foundation Network. The study involves both retrospective and prospective data collection. It will enroll both patients already under care for follow-up and newly diagnosed patients.

A sample of at least 300 children and/or adolescents with CP of various etiologies, with 100 participants per clinical center, is targeted. Enrollment will be voluntary, either by invitation from the referring physician, who will explain the importance of the registry, or through project dissemination, allowing parents to request their children's inclusion. Basic registry items can be filled out by parents and, with permission, the primary physician for clinical fields. Parents can opt to be included in the registry to receive information on national clinical studies, approved by ethics committees.

Collected essential data includes:

  • Identification and contact information for patient pseudonymization
  • Socioeconomic status
  • CP classification according to the European Surveillance Group
  • Anamnesis regarding disorder etiology
  • Neuroradiological classification based on SCPE (MRICS)
  • Functional impairment level of each child
  • Significant comorbidities

STUDY POPULATION At least 300 pediatric CP patients aged 4-18 years are expected to be recruited. Exclusion criteria only include lack of informed consent.

DRUG, MEDICAL DEVICE, NUTRACEUTICAL, BIOLOGICAL SAMPLES, OTHER ELEMENTS This observational study involves systematic, standardized retrospective and prospective data collection of clinical, instrumental, and genetic data (if available). No medical devices, pharmaceuticals, or nutraceuticals will be used. No human biological samples will be collected.

STUDY TIMELINE Study duration per patient: aligned with routine clinical visits. No additional evaluations are foreseen.

Recruitment duration: 12 months Overall study duration: 36 months

SAMPLE SIZE AND DATA ANALYSIS The study aims to recruit at least 300 pediatric CP patients. A control group is not planned.

03

Conditions studied

  • Cerebral Palsy

Browse trials for

Keywords

  • Cerebral palsy
  • Database
  • Hospital-based registry
04

Who can participate

Ages eligible
4 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population is expected to include at least 300 pediatric patients with cerebral palsy (CP) in accordance with the inclusion and exclusion criteria outlined by the SCPE Collaborative Group (2000).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of cerebral palsy (CP) confirmed clinically in accordance with recent international guidelines (SCPE Guidelines, 2019);
  • Age between 4 and 18 years.

Exclusion criteria

Exclusion Criteria:

  • Progressive neuromotor disorder (defined as a condition involving the loss of previously acquired abilities);
  • Patients with a neurological condition defined by isolated hypotonia;
  • Patients with neurological deficits secondary to spinal injury;
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
300 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Children with CP

    Children with diagnosed CP age: 4-18 years old

    Other: hospital-based registry

Interventions

  • Otherhospital-based registry

    The clinical data collected for each patient will reflect comprehensive multiprofessional clinical insights necessary for diagnostic definition and typically obtained during diagnostic evaluation and/or monitoring visits. In addition to these, instrumental data commonly acquired in clinical practice, such as neuroradiological and electrophysiological information, will also be collected. For each enrolled subject, a checklist (CRF) will be completed to gather study-related data. These data will be entered into a specific database constructed on the REDCap platform and managed in an anonymized form. Subject enrollment will be conducted progressively. This data collection will enable monitoring of study progress, including the number of enrolled subjects, completed assessments, and study adherence. Every three months, monitoring will be performed to assess study progress and the achievement of enrollment targets.

06

What researchers measure

Primary outcomes

  1. Participants demographic data

    Age, gender, birth date, place of birth, nationality, address (country)

    Time frame: Baseline

  2. Cerebral palsy (CP) classification

    Classification of CP according to the European Surveillance Group (SCPE Guidelines, 2019): Spastic CP (bilateral or unilateral forms); Dyskinetic CP (dystonic form or choreoathetotic form); Ataxic CP.

    Time frame: Baseline

  3. Anamnestic data related to the etiopathogenesis of the disorder

    This refers to the medical history and background information that help in understanding the cause and development of a disorder i.e. visual and auditory impairments, birth weight, cognitive level, epilepsy, Apgar score and comorbidities.

    Time frame: Baseline

  4. Level of Gross Motor Function Classification System (GMFCS)

    The Gross Motor Function Classification System (GMFCS), is a five-level classification that differentiates children with cerebral palsy based on the child's current gross motor abilities, limitations in gross motor function, and need for assistive technology and wheeled mobility (Rosenbaum et al., 2008).

    Time frame: Baseline

  5. Level of Manual Ability Classification System (MACS)

    Manual Ability Classification System (MACS) classifies the child's ability from 4 to 18 years old to handle objects in daily activities on one of 5 levels (level I: greater ability, level V: less ability). MACS level I (able to handle objects easily and successfully), level II (able to handle most objects but with somewhat reduced quality and/or speed of achievement so that alternate ways of performance might be used), level III (handles objects with difficulty; needs help to prepare and/or modify activities), level IV (needs continuous support, handles a limited selection of objects), level V (does not handle objects, needs total assistance) (Eliasson et al., 2006).

    Time frame: Baseline

  6. Level of Bimanual Fine Motor Function (BFMF)

    Bimanual Fine Motor Function (BFMF) classifies fine motor function according to the child's best ability (capacity) to grasp, hold and manipulate objects for each hand separately. BFMF can be used in children from 3-18 years of age (Elvrum et al., 2016).

    Time frame: Baseline

  7. Level of Visual Function Classification System (VFCS)

    The Visual Function Classification System (VFCS) is a tool used to classify the level of visual function in individuals with disabilities, particularly in the context of cerebral palsy. It is divided into five levels, each describing the degree of visual ability and the impact on daily activities (Baranello et al., 2020).

    Time frame: Baseline

  8. Level of Communication Function Classification System (CFCS)

    The Communication Function Classification System (CFCS) is a classification tool used to assess and categorize the communication abilities of individuals with cerebral palsy or similar disabilities. It is divided into five levels, each describing the individual's ability to communicate in different environments with both familiar and unfamiliar partners.

    Time frame: Baseline

  9. Level of Viking Speech Scale (VSS)

    The Viking Speech Scale (VSS) is a classification system designed to assess and categorize the speech abilities of individuals with cerebral palsy or other neurological conditions that affect communication. It focuses on the clarity and intelligibility of speech, as well as the individual's ability to communicate effectively with others. The scale is divided into four levels (Pennington et al., 2013).

    Time frame: Baseline

  10. Level of Eating and Drinking Classification System (EDACS)

    The Eating and Drinking Classification System (EDACS) is a tool used to classify the eating and drinking abilities of individuals with disabilities, particularly in the context of cerebral palsy. It categorizes individuals into different levels based on their ability to safely and efficiently eat and drink, with a focus on both the safety and efficiency of these activities. The system is divided into five levels (Sellers et al., 2014).

    Time frame: Baseline

  11. Neuroradiological classification according to the classification promoted by SCPE (MRICS)

    Magnetic Resonance Imaging Classification System is used in the context of neuroradiological assessment in cerebral palsy. A. Maldevelopments A.1. Disorders of cortical formation (proliferation and/or migration and/or organization A.2. Other maldevelopments (examples: holoprosencephaly Dandy-Walker malformation, corpus callosum agenesis, cerebellar hypoplasia) B. Predominant white matter injury B.1. PVL (mild/severe) B.2. Sequelae of IVH or periventricular haemorrhagic infarction B.3. Combination of PVL and IVH sequelae C. Predominant grey matter injury C.1. Basal ganglia/thalamus lesions (mild/moderate/severe) C.2. Cortico-subcortical lesions only (watershed lesions in parasagittal distribution/multicystic encephalomalacia) not covered under C3 C.3. Arterial infarctions (middle cerebral artery/other) D. Miscellaneous (examples: cerebellar atrophy, cerebral atrophy, delayed myelination, ventriculomegaly not covered under B, haemorrhage not covered under B, brainstem lesions, calcific

    Time frame: Baseline

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Pennington L, Virella D, Mjoen T, da Graca Andrada M, Murray J, Colver A, Himmelmann K, Rackauskaite G, Greitane A, Prasauskiene A, Andersen G, de la Cruz J. Development of The Viking Speech Scale to classify the speech of children with cerebral palsy. Res Dev Disabil. 2013 Oct;34(10):3202-10. doi: 10.1016/j.ridd.2013.06.035. Epub 2013 Jul 24. PubMed 23891732 ↗
  • Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, Jacobsson B, Damiano D; Executive Committee for the Definition of Cerebral Palsy. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005 Aug;47(8):571-6. doi: 10.1017/s001216220500112x. PubMed 16108461 ↗
  • Baranello G, Signorini S, Tinelli F, Guzzetta A, Pagliano E, Rossi A, Foscan M, Tramacere I, Romeo DMM, Ricci D; VFCS Study Group. Visual Function Classification System for children with cerebral palsy: development and validation. Dev Med Child Neurol. 2020 Jan;62(1):104-110. doi: 10.1111/dmcn.14270. Epub 2019 Jun 10. PubMed 31180136 ↗
  • Himmelmann K, Horber V, De La Cruz J, Horridge K, Mejaski-Bosnjak V, Hollody K, Krageloh-Mann I; SCPE Working Group. MRI classification system (MRICS) for children with cerebral palsy: development, reliability, and recommendations. Dev Med Child Neurol. 2017 Jan;59(1):57-64. doi: 10.1111/dmcn.13166. Epub 2016 Jun 21. PubMed 27325153 ↗
  • Sellers D, Mandy A, Pennington L, Hankins M, Morris C. Development and reliability of a system to classify the eating and drinking ability of people with cerebral palsy. Dev Med Child Neurol. 2014 Mar;56(3):245-51. doi: 10.1111/dmcn.12352. Epub 2013 Dec 18. PubMed 24344767 ↗
  • Fiori S, Cioni G, Klingels K, Ortibus E, Van Gestel L, Rose S, Boyd RN, Feys H, Guzzetta A. Reliability of a novel, semi-quantitative scale for classification of structural brain magnetic resonance imaging in children with cerebral palsy. Dev Med Child Neurol. 2014 Sep;56(9):839-45. doi: 10.1111/dmcn.12457. Epub 2014 Apr 19. PubMed 24750109 ↗
  • Elvrum AK, Andersen GL, Himmelmann K, Beckung E, Ohrvall AM, Lydersen S, Vik T. Bimanual Fine Motor Function (BFMF) Classification in Children with Cerebral Palsy: Aspects of Construct and Content Validity. Phys Occup Ther Pediatr. 2016;36(1):1-16. doi: 10.3109/01942638.2014.975314. Epub 2014 Nov 6. PubMed 25374154 ↗
  • Eliasson AC, Krumlinde-Sundholm L, Rosblad B, Beckung E, Arner M, Ohrvall AM, Rosenbaum P. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol. 2006 Jul;48(7):549-54. doi: 10.1017/S0012162206001162. PubMed 16780622 ↗
  • Long HL, Mahr TJ, Natzke P, Rathouz PJ, Hustad KC. Longitudinal change in speech classification between 4 and 10 years in children with cerebral palsy. Dev Med Child Neurol. 2022 Sep;64(9):1096-1105. doi: 10.1111/dmcn.15198. Epub 2022 Mar 9. PubMed 35262181 ↗
  • Rosenbaum PL, Palisano RJ, Bartlett DJ, Galuppi BE, Russell DJ. Development of the Gross Motor Function Classification System for cerebral palsy. Dev Med Child Neurol. 2008 Apr;50(4):249-53. doi: 10.1111/j.1469-8749.2008.02045.x. Epub 2008 Mar 1. PubMed 18318732 ↗
  • Sellier E, Surman G, Himmelmann K, Andersen G, Colver A, Krageloh-Mann I, De-la-Cruz J, Cans C. Trends in prevalence of cerebral palsy in children born with a birthweight of 2,500 g or over in Europe from 1980 to 1998. Eur J Epidemiol. 2010 Sep;25(9):635-42. doi: 10.1007/s10654-010-9474-0. Epub 2010 Jun 8. PubMed 20532622 ↗
  • Scheck SM, Pannek K, Fiori S, Boyd RN, Rose SE. Quantitative comparison of cortical and deep grey matter in pathological subtypes of unilateral cerebral palsy. Dev Med Child Neurol. 2014 Oct;56(10):968-75. doi: 10.1111/dmcn.12461. Epub 2014 Apr 19. PubMed 24749496 ↗
  • Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev Med Child Neurol. 2000 Dec;42(12):816-24. doi: 10.1017/s0012162200001511. PubMed 11132255 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2026, 36 months after the start.

Of 217 non-industry observational studies under Cerebral Palsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 60. This study's planned 36 months is above that.

Counting every sponsor, half of 221 studies reached it within 21 months; a quarter within 8 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 7, 2025
StartActual
Jun 1, 2023
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06813586
Lead sponsor
IRCCS Fondazione Stella Maris
Collaborators
Fondazione Pierfranco e Luisa Mariani, Fondazione FightTheStroke, Istituto Superiore di Sanità, IRCCS Eugenio Medea, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Responsible party
Giuseppina Sgandurra (Associate Professor, Head of INNOVATE Lab, IRCCS Fondazione Stella Maris) — Principal investigator
First posted
Feb 7, 2025
Start date
Jun 1, 2023
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Feb 7, 2025

Study contacts

Giuseppina Sgandurra MD, PhD
Contact
giuseppina.sgandurra@fsm.unipi.it
050886284

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion